QCM Cayman’s Madrigal Pharmaceuticals MDGL Stock Holding History

QCM Cayman’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-320	Closed	-$4K	–	227
2015 Q4	$4K	Buy	+320	New	+$8.78K	﹤0.01%	141

Other funds holding MDGL

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

QCM Cayman's MDGL Position: Q1 2016 in Review

QCM Cayman sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2016, closing a stake of 320 shares — an estimated $4K sold.

QCM Cayman first reported a position in MDGL in Q4 2015 and held it in 1 quarter. The position peaked at $4K in Q4 2015. 68 funds tracked by Wall St. Rank hold MDGL as of Q1 2016.

QCM Cayman reported no remaining Madrigal Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
QCM Cayman sold 320 Madrigal Pharmaceuticals shares in Q1 2016, an estimated $4K.
QCM Cayman first reported a position in Madrigal Pharmaceuticals in Q4 2015 and held it in 1 quarter.
QCM Cayman's Madrigal Pharmaceuticals position peaked at $4K in Q4 2015.
68 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2016.

Based on QCM Cayman's 13F filing for Q1 2016, filed 16 May 2016.